rivoceranib,camrelizumab
jiangsu hengrui pharmaceuticals,elevar therapeutics
['lba3', 'hcc', 'camrelizumab', 'lba35', 'rivoceranib', 'elevar']
you can watch the proffered paper presentation session of our phase 3 data of rivoceranib in combination with camrelizumab for unresectable hepatocellular carcinoma (uhcc) on demand (proffered paper presentation, poster #lba35) on the #esmo22 website. 
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients.